C4 Therapeutics Inc (NASDAQ:CCCC) price on Wednesday, December 04, fall -3.69% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $3.91.
A look at the stock’s price movement, the close in the last trading session was $4.06, moving within a range at $3.79 and $4.095. The beta value (5-Year monthly) was 3.056. Turning to its 52-week performance, $11.88 and $1.06 were the 52-week high and 52-week low respectively. Overall, CCCC moved -39.38% over the past month.
C4 Therapeutics Inc’s market cap currently stands at around $276.00 million, with investors looking forward to this quarter’s earnings report slated for in January.
The average forecast suggests up to a 10.40% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 35.76M, representing a 72.28% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CCCC is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 1 recommend CCCC as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Hold which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CCCC’s current price about -17.00% and -27.40% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 33.05, while 7-day volatility ratio is 6.90% and 8.32% in the 30-day chart. Further, C4 Therapeutics Inc (CCCC) has a beta value of 2.94, and an average true range (ATR) of 0.38. Analysts have given the company’s stock an average 52-week price target of $20, forecast between a low of $20 and high of $20. Looking at the price targets, the low is -411.51% off current price level while to achieve the yearly target high, price needs to move -411.51%. Nonetheless, investors will most likely welcome a -411.51% jump to $20 which is the analysts’ median price.
If we refocus on C4 Therapeutics Inc (NASDAQ:CCCC), historical trading data shows that trading volumes averaged 1.25 over the past 10 days and 1.04 million over the past 3 months. The company’s latest data on shares outstanding shows there are 70.56 million shares.
The 19.72% of C4 Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 83.28% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 7.4 million on 2024-11-15, giving us a short ratio of 8.36. The data shows that as of 2024-11-15 short interest in C4 Therapeutics Inc (CCCC) stood at 1270.0 of shares outstanding, with shares short rising to 6.65 million registered in 2024-10-15. Current price change has pushed the stock -30.80% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CCCC stock continues to rise going into the next quarter.
